|
Advanced search
Previous page
|
Title
Trends in access to anti-malarial treatment in the formal private sector in Uganda: an assessment of availability and affordability of first-line anti-malarials and diagnostics between 2007 and 2018 |
Full text
https://dspace.library.uu.nl/handle/1874/411671 |
Date
2021 |
Author(s)
Kibira, Denis; Ssebagereka, Anthony; van den Ham, Hendrika A.; Opigo, Jimmy; Katamba, Henry; Seru, Morries; Reed, Tim; Leufkens, Hubert G.; Mantel-Teeuwisse, Aukje K. |
Contributor(s)
Afd Pharmacoepi & Clinical Pharmacology; Pharmacoepidemiology and Clinical Pharmacology |
Abstract
Background: Malaria is the single largest cause of illness in Uganda. Since the year 2008, the Global Fund has rolled out several funding streams for malaria control in Uganda. Among these are mechanisms aimed at increasing the availability and affordability of artemisinin-based combination therapy (ACT). This paper examines the availability and affordability of first-line malaria treatment and diagnostics in the private sector, which is the preferred first point of contact for 61% of households in Uganda between 2007 and 2018. Methods: Cross-sectional surveys were conducted between 2007 and 2018, based on a standardized World Health Organization/Health Action International (WHO/HAI) methodology adapted to assess availability, patient prices, and affordability of ACT medicines in private retail outlets. A minimum of 30 outlets were surveyed per year as prescribed by the standardized methodology co-developed by the WHO and Health Action International. Availability, patient prices, and affordability of malaria rapid diagnostic tests (RDTs) was also tracked from 2012 following the rollout of the test and treat policy in 2010. The median patient prices for the artemisinin-based combinations and RDTs was calculated in US dollars (USD). Affordability was assessed by computing the number of days' wages the lowest-paid government worker (LPGW) had to pay to purchase a treatment course for acute malaria. Results: Availability of artemether/lumefantrine (A/L), the first-line ACT medicine, increased from 85 to100% in the private sector facilities during the study period. However, there was low availability of diagnostic tests in private sector facilities ranging between 13% (2012) and 37% (2018). There was a large reduction in patient prices for an adult treatment course of A/L from USD 8.8 in 2007 to USD 1.1 in 2018, while the price of diagnostics remained mostly stagnant at USD 0.5. The affordability of ACT medicines and RDTs was below one day's wages for LPGW. Conclusions: Availability of ACT medicines in the private sector medicines retail outlets increased to 100% while the availability of diagnostics remained low. Although malaria treatment was affordable, the price of diagnostics remained stagnant and increased the cumulative cost of malaria management. Malaria stakeholders should consolidate the gains made and consider the inclusion of diagnostic kits in the subsidy programme. |
Subject(s)
Access; Affordability; Antimalarial medicines; Artemisinin-based combination therapies; Availability; Diagnostics; Global Fund; Private sector; Parasitology; Infectious Diseases |
Language
en |
Relation
1475-2875 |
Type of publication
Article |
Format
application/pdf |
Rights
info:eu-repo/semantics/OpenAccess |
Identifier
Malaria Journal 20(1), 1-8 (2021) |
Repository
Utrecht - University of Utrecht
|
Added to C-A: 2022-06-27;09:14:27 |
© Connecting-Africa 2004-2024 | Last update: Saturday, July 6, 2024 |
Webmaster
|